FDA Approves Jeuveau PrabotulinumtoxinA-xvfs

New Neurotoxin Enters Market

There is a new injectable neurotoxin coming to the aesthetics market. On February 1, the U.S. Food and Drug Administration approved Evolus’ Jeuveau (prabotulinumtoxinA-xvfs) for temporary improvement in the appearance of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. Jeuveau is a proprietary 900 kDa purified botulinum toxin type A formulation.